A Phase 2 Evaluation of Anti-VEGF Therapy for Diabetic Macular Edema: Bevacizumab (Avastin).
Phase of Trial: Phase II
Latest Information Update: 03 Sep 2016
At a glance
- Drugs Bevacizumab (Primary)
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- 11 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 Jul 2011 Actual end date (Feb 2008) added as reported by ClinicalTrials.gov.
- 11 Jul 2011 Additional lead trial centers added as reported by ClincialTrials.gov.